Onco-Innovations and AstraZeneca Collaboration in AI-Oncology Consortium

Onco-Innovations Limited announces that its subsidiary, Inka Health Corp., has received an Expression of Interest from AstraZeneca to join the Predictive Oncology Outcomes using Multimodal AI (PROmAI) Consortium. This partnership aims to utilize AI for improving predictive oncology research.

The PROmAI Consortium, led by Inka Health, will bring together pharmaceutical companies and scientific experts. It focuses on developing AI methodologies for predicting oncology outcomes. By integrating real-world data with causal AI, the consortium seeks to enhance predictive modeling in oncology.

AstraZeneca's involvement emphasizes the relevance of this initiative, aiming to align AI applications with regulatory requirements. Discussions with other pharmaceutical firms for consortium participation are ongoing, with future updates anticipated.